A Phase II Study of the Adjuvant Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFR-425) Monoclonal Antibody [anti-EGFR monoclonal antibody 425] Radiolabeled With I-125 [iodine 125] for High Grade Gliomas
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Anti-EGFR monoclonal antibody 425 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 08 May 2017 Status changed from suspended to completed.
- 16 Jun 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 01 Feb 2008 New trial record.